Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genaera progressing with eye drug trials
One of the studies, MSI-1256F-208, is a phase II trial designed to evaluate the effects of three different doses of squalamine in combination with an initial Visudyne treatment.
One of the studies, MSI-1256F-208, is a phase II trial designed to evaluate the effects of three different doses of squalamine in combination with an initial Visudyne treatment.
The primary endpoint was to increase platelet counts by 20,000 at 48 hours after dosing. Platelets perform a critical role in the body’s blood clotting system and low
The six month priority review for the supplemental new drug application (sNDA), sets the prescription drug user fee act (PDUFA) date to June 10, 2005. Solvay Pharmaceuticals holds
In the transaction, Cornerstone BioPharma will transfer the Humibid family of products, including over-the-counter (OTC) medications and prescription strength products to Adams Laboratories. In exchange, Adams Laboratories will
Organon will receive exclusive rights to targets identified by Entelos and access to Entelos’ research capabilities from discovery to approval. Entelos will receive co-promotion and commercialization rights for
Under the alliance, Cellular Genomics (CGI) has been applying its proprietary chemical genetics analog sensitive kinase (ASKA) technology to a number of target kinases selected by Serono. The
Seattle Genetics entered into the antibody-drug conjugate (ADC) collaboration with CuraGen in June 2004, at which time CuraGen paid an upfront fee of $2 million for access to
This is the first study to evaluate the company’s oral lead product candidate, talabostat (PT-100), as a single agent in patients with advanced metastatic melanoma. The trial is
The independent drug safety oversight board will oversee the management of important safety issues such as recommending information and updates for placement on the Drug Watch, resolving disagreements
Under the terms of the agreement, Avalon will hold exclusive rights to develop and commercialize VX-944 worldwide for the treatment of various cancers. Avalon will make up to